Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

被引：0
|
作者：
Shuxia Qin
Lidan Yi
Sini Li
Chongqing Tan
Xiaohui Zeng
Liting Wang
Ye Peng
Xiaomin Wan
机构：
[1] Central South University,Department of Pharmacy, The Second Xiangya Hospital
[2] Central South University,Xiangya Nursing School
[3] Central South University,PET
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Atezolizumab; Bladder cancer; Cost-effectiveness; Markov model; Urothelial carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3399 / 3408
页数：9
相关论文
共 50 条
  • [1] Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer
    Qin, Shuxia
    Yi, Lidan
    Li, Sini
    Tan, Chongqing
    Zeng, Xiaohui
    Wang, Liting
    Peng, Ye
    Wan, Xiaomin
    ADVANCES IN THERAPY, 2021, 38 (06) : 3399 - 3408
  • [2] Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
    Liu, Xiaoyan
    Lang, Yitian
    Chai, Qingqing
    Lin, Yan
    Liao, Yahui
    Zhu, Yizhun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Wen, Feng
    Wu, Qiu-Ji
    Li, Qiu
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1021 - 1030
  • [4] Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US
    Lin, Yingtao
    Li, Cijuan
    Wang, Chang
    Chen, Jian
    Huang, Yuanqing
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [5] Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma
    Wang, Siying
    Xie, Ouyang
    Wu, Meiyu
    Xiang, Heng
    Tan, Chongqing
    Wan, Xiaomin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 173 - 178
  • [6] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
    Wu, Meiyu
    Qin, Shuxia
    Wang, Liting
    Tan, Chongqing
    Peng, Ye
    Zeng, Xiaohui
    Luo, Xia
    Yi, Lidan
    Wan, Xiaomin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma
    Lin, Jingwen
    Song, Xiaobing
    Fu, Wu
    You, Caicong
    Li, Na
    Liu, Maobai
    Cai, Hongfu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [8] Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
    Pei, Zhengda
    Xiao, Ningping
    Yang, Pei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis
    Lei, Jianying
    Zhang, Jiahao
    You, Caicong
    Liu, Maobai
    Li, Na
    VALUE IN HEALTH, 2024, 27 (11) : 1528 - 1534
  • [10] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Liao, Mengting
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Huang, Jin
    ADVANCES IN THERAPY, 2020, 37 (05) : 2116 - 2126
12345